All Courses
>
American Journal of Psychiatry
>
Courses by Date
>
2008
>
AJP CME Course for February 2008: Impact of Clinical Training on Violence Risk Assessment
AJP CME Course for February 2008: Impact of Clinical Training on Violence Risk Assessment
Information to Participants
OBJECTIVES. After evaluating a specific journal article, participants should be able to demonstrate an increase in their knowledge of clinical medicine. Participants should be able to understand the contents of a selected research or review article and to apply the new findings to their clinical practice.
PARTICIPANTS. This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.
EXPLANATION OF HOW PHYSICIANS CAN PARTICIPATE AND EARN CREDIT. In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the CME quiz online at cme.psychiatryonline.org and submit your evaluation and study hours (up to 1 AMA PRA Category 1 CreditTM).
CREDITS. The American Psychiatric Association designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Estimated Time to Complete Course: 1 hour
Begin Date for Course: February 1, 2008
End Date for Course: January 31, 2010
Information on Course
Title: Impact of Clinical Training on Violence Risk Assessment
Faculty: Dale E. McNiel, Ph.D., John R. Chamberlain, M.D., Christopher M. Weaver, Ph.D., Stephen E. Hall, M.D., Samantha R. Fordwood, Ph.D., Renée L. Binder, M.D.
Affiliation: Department of Psychiatry, University of California, San Francisco
Disclosures: Dr. Chamberlain has been on the speakers bureaus of Bristol-Myers Squibb, Pfizer, and Wyeth. Dr. Hall has been on the speakers bureaus and consulted for Bristol-Myers Squibb, Eli Lilly, AstraZeneca, and Pfizer. The remaining authors report no competing interests.
Discussion of unapproved or investigational use of products*: None
*American Psychiatric Association policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.
Copyright © 2008 by American Psychiatric Publishing, Inc